Wordt geladen...
Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative colitis (UC). A range of 5-ASA preparations is available and Eudragit-S(®) coated modified release formulations of mesalamine, such as Asacol(®), remain among the most popular choices. We here review the current...
Bewaard in:
| Hoofdauteurs: | , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2009
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3108647/ https://ncbi.nlm.nih.gov/pubmed/21694838 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|